Drug Profile
NERx 505
Alternative Names: NERx-505Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator NERx Biosciences
- Class Small molecules
- Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Mar 2022 NERx 505 is still in preclinical development for Cancer in USA
- 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Bioscience pipeline, September 2016)
- 27 Sep 2016 NERx Biosciences receives SBIR grant from National Cancer Institute for NERx 505 development in Cancer before September 2016 (NERx pipeline, September 2016)